646 related articles for article (PubMed ID: 10828533)
1. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
3. Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.
Lastres-Becker I; Gómez M; De Miguel R; Ramos JA; Fernández-Ruiz J
Neurotox Res; 2002; 4(7-8):601-608. PubMed ID: 12709298
[TBL] [Abstract][Full Text] [Related]
4. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease.
Morton AJ; Nicholson LF; Faull RL
Neuroscience; 1993 Mar; 53(1):159-68. PubMed ID: 7682296
[TBL] [Abstract][Full Text] [Related]
5. The diversity of GABA(A) receptor subunit distribution in the normal and Huntington's disease human brain.
Waldvogel HJ; Faull RL
Adv Pharmacol; 2015; 73():223-64. PubMed ID: 25637443
[TBL] [Abstract][Full Text] [Related]
6. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical substrates of rigidity and chorea in Huntington's disease.
Storey E; Beal MF
Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
[TBL] [Abstract][Full Text] [Related]
8. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Glass M; Faull RL; Dragunow M
Neuroscience; 1993 Oct; 56(3):523-7. PubMed ID: 8255419
[TBL] [Abstract][Full Text] [Related]
9. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
10. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
11. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.
Richfield EK; Herkenham M
Ann Neurol; 1994 Oct; 36(4):577-84. PubMed ID: 7944290
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
13. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.
Dayne Mayfield R; Larson G; Orona RA; Zahniser NR
Synapse; 1996 Feb; 22(2):132-8. PubMed ID: 8787129
[TBL] [Abstract][Full Text] [Related]
14. Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.
Glaser T; Andrejew R; Oliveira-Giacomelli Á; Ribeiro DE; Bonfim Marques L; Ye Q; Ren WJ; Semyanov A; Illes P; Tang Y; Ulrich H
Neurosci Bull; 2020 Nov; 36(11):1299-1314. PubMed ID: 33026587
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous dopamine receptor changes in early and late Huntington's disease.
Richfield EK; O'Brien CF; Eskin T; Shoulson I
Neurosci Lett; 1991 Oct; 132(1):121-6. PubMed ID: 1838580
[TBL] [Abstract][Full Text] [Related]
16. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia.
Page KJ; Besret L; Jain M; Monaghan EM; Dunnett SB; Everitt BJ
Exp Brain Res; 2000 Jan; 130(2):142-50. PubMed ID: 10672467
[TBL] [Abstract][Full Text] [Related]
17. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene.
O'Kusky JR; Nasir J; Cicchetti F; Parent A; Hayden MR
Brain Res; 1999 Feb; 818(2):468-79. PubMed ID: 10082833
[TBL] [Abstract][Full Text] [Related]
18. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats.
Romero J; Berrendero F; Garcia-Gil L; de la Cruz P; Ramos JA; Fernández-Ruiz JJ
Neuroscience; 1998 Jun; 84(4):1075-83. PubMed ID: 9578396
[TBL] [Abstract][Full Text] [Related]
19. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.
Herkenham M; Lynn AB; de Costa BR; Richfield EK
Brain Res; 1991 May; 547(2):267-74. PubMed ID: 1909204
[TBL] [Abstract][Full Text] [Related]
20. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
